Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

Rajan Sharma (Contributor), Alicia Norman (Contributor), Martin Hoyle (Contributor), Henry Cutler (Contributor)

Research output: Book/ReportCommissioned report

Fingerprint

Dive into the research topics of 'Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)'. Together they form a unique fingerprint.